Abstract:Molecular medicine is an emerging field focused on understanding the molecular basis of diseases and translating this information into strategies for diagnosis and therapy. This approach could lead to personalized medical treatments. Currently, our ability to understand human diseases at the molecular level is limited by the lack of molecular tools to identify and characterize the distinct molecular features of the disease state, especially for diseases such as cancer. Among the new tools being developed by researchers including chemists, engineers, and other scientists is a new class of nucleic acid probes called aptamers, which are ssDNA/RNA molecules selected to target a wide range of molecules and even cells. In this Account, we will focus on the use of aptamers, generated from cell-based selections, as a novel molecular tool for cancer research. Cancers originate from mutations of human genes. These genetic alterations result in molecular changes to diseased cells, which, in turn, lead to changes in cell morphology and physiology. For decades, clinicians have diagnosed cancers primarily based on the morphology of tumor cells or tissues. However, this method does not always give an accurate diagnosis and does not allow clinicians to effectively assess the complex molecular alterations that are predictive of cancer progression. As genomics and proteomics do not yet allow a full access to this molecular knowledge, aptamer probes represent one effective and practical avenue toward this goal. One special feature of aptamers is that we can isolate them by selection against cancer cells without prior knowledge of the number and arrangement of proteins on the cellular surface. These probes can identify molecular differences between normal and tumor cells and can discriminate among tumor cells of different classifications, at different disease stages, or from different patients. This Account summarizes our recent efforts to develop aptamers through cell-SELEX for the study of cancer and apply those aptamers in cancer diagnosis and therapy. We first discuss how we select aptamers against live cancer cells. We then describe uses of these aptamers. Aptamers can serve as agents for molecular profiling of specific cancer types. They can also be used to modify therapeutic reagents to develop targeted cancer therapies. Aptamers are also aiding the discovery of new cancer biomarkers through the recognition of membrane protein targets. Importantly, we demonstrate how molecular assemblies can integrate the properties of aptamers and, for example, nanoparticles or microfluidic devices, to improve cancer cell enrichment, detection and therapy.

Aptamer-drug Conjugation for Targeted Tumor Cell Therapy.

Aptamers: an Emerging Navigation Tool of Therapeutic Agents for Targeted Cancer Therapy

Novel Insights into the Role of Aptamers in the Fight Against Cancer.

Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach

The application progress in cell-SELEX-based aptamers in cancer

Aptamers as an approach to targeted cancer therapy

Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy

Nucleic acid aptamer application in diagnosis and therapy of colorectal cancer based on cell-SELEX technology

Advancing Aptamers as Molecular Probes for Cancer Theranostic Applications—The Role of Molecular Dynamics Simulation

Aptamer-based Cell Recognition and Detection

RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule

Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy

Aptamer and Aptamer Pharmaceuticals

Tumor-Targeted Drug Delivery With Aptamers

Advances in the Development of Aptamer Drug Conjugates for Targeted Drug Delivery.

Advances In The Development Of Aptamer Drug Conjugates For Targeted Drug Delivery

Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery

Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy

Smart ligand: Aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy

In Silico Design and Validation of High-Affinity RNA Aptamers Targeting Epithelial Cellular Adhesion Molecule Dimers

Selection of trophoblast cell surface antigen 2-targeted aptamer for the development of cytotoxic aptamer-drug conjugate